Resource utility {#S1}
================

This human induced pluripotent stem cell (hiPSC) line is a useful tool for studying disease pathophysiology and as a cell-based disease model for drug development to treat Pompe disease.

Resource details {#S2}
================

Pompe disease, also known as glycogen storage disease type II, is a rare autosomal recessive disorder caused by mutations in the *GAA* gene that results in a deficiency of lysosomal acid α-glucosidase (GAA). GAA facilitates the glycogen degradation by cleavage α-1,4 and α-1,6 linkages in glycogen. Deficiency in GAA results in accumulation of glycogen within lysosomes and in cytoplasm, eventually leading to tissue destruction. Infantile Pompe disease is the most severe subtype; disease symptoms occur in the first few months of life including muscle weakness, hypotonia, respiratory insufficiency and hypertrophic cardiomyopathy ([@R3]). On the other hand, late-onset Pompe disease may present at any age with slowly progressive proximal myopathy.

In this study, we generated a human iPSC line (TRNDi007-B) from patient skin fibroblasts (GM00248) which was isolated from a five-month-old male patient carrying a homozygous mutation (c.2560C \> T, p.R854X) in exon 18 of the *GAA* gene. R854X mutation is a well-documented African-American mutation and the homozygous mutation is responsible for severe infantile-onset Pompe disease ([@R1]). Patient fibroblasts were reprogramed into iPSC by transduction a set of non-integrating Sendai virus vectors encoding *OCT3/4, KLF4, S0X2 and C-MYC* genes ([@R2]). A single iPSC colony, termed TRNDi007-B, was isolated and characterized for future applications. [Fig. 1A](#F1){ref-type="fig"} show that the iPSC line presents a standard iPSC morphology and expressed major pluripotent protein markers including SOX2, NANOG, OCT4, and SSEA-4 in the immunocytochemistry assay. The pluripotency markers including TRA-1-60, SSEA-4, and NANOG were also detected and quantified by the flow cytometry analysis ([Fig. 1B](#F1){ref-type="fig"}). The mutation (c.2560C \> T) in the GAA gene was confirmed by targeted Sanger sequencing where the PCR product harbors a single nucleotide variation (SNV) in both alleles ([Fig. 1D](#F1){ref-type="fig"}). At passage 7, cells showed a normal human karyotype (46, XY) ([Fig. 1C](#F1){ref-type="fig"}). The clearance of Sendai virus vectors and the exogenous reprogramming factor genes were verified by reverse transcription polymerase chain reaction (RT-PCR) at passage 17 ([Fig. 1E](#F1){ref-type="fig"}). The iPSCs were free of mycoplasma ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}) and the cell identity was proved by the short tandem repeat analysis (information available with the authors). Furthermore, the three-germ-layer differentiation capacity was demonstrated by the teratoma formation assay (Ectoderm, pigment epithelium; Mesoderm, cartilage; Endoderm, gut-like endoderm) *in vivo* ([Fig. 1F](#F1){ref-type="fig"}).

Materials and methods {#S3}
=====================

Cell culture {#S4}
------------

Human skin fibroblasts (GM00248) were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for medical research and maintained in DMEM containing 10% fetal bovine serum (HyClone), 100 units/mL penicillin, and 100 units/mL streptomycin. Human iPSCs were cultured in StemFlex medium (Thermo Fisher Scientific) on Geltrex-coated plates at 37 °C in humidified air with 5% CO~2~ and 5% O~2~. Dulbecco\'s Phosphate Buffered Saline (DPBS) containing 0.5mM ethylenediaminetetraacetic acid (EDTA) was employed during passaging ([Table 1](#T1){ref-type="table"}).

Reprogramming of human skin fibroblasts {#S5}
---------------------------------------

Patient fibroblasts were reprogrammed into iPSCs using a Sendai virus based kit (A16517, Thermo Fisher Scientific) as described previously ([@R2]).

Mutation analysis {#S6}
-----------------

The genomic mutation analysis was carried out by Applied StemCell (Milpitas, CA). Genomic DNA was extracted using QuickExtract™ DNA Extraction Solution (Lucigen). PCR amplification was performed with MyTaq™ Red Mix (Bioline, Taunton, MA) and specific primers ([Table 2](#T2){ref-type="table"}). Amplifications were carried out on T00 Thermal Cycler (Bio-Rad \#1861096) using the following condition: 2 min at 95 °C, 30 cycles of (15 s at 95 °C, 15 s at 60 °C, 15 s at 72 °C), and 72 °C for 5 min. The PCR products were Sanger sequenced.

Immunocytochemistry {#S7}
-------------------

Cells were fixed in 4% paraformaldehyde for 20 min, rinsed with DPBS, and permeabilized with 0.5% Triton X-100/DPBS for 10 min at room temperature in a 96-well format. After blocked in cell staining buffer (BioLegend, CA) for 1 h at room temperature, cells were stained with primary antibodies/staining buffer ([Table 2](#T2){ref-type="table"}) for overnight at 4 °C. Cells were washed three times with DPBS and incubated with matched secondary antibodies ([Table 2](#T2){ref-type="table"}) for 1 h at room temperature. Cells were washed with DPBS again and stained with Hoechst 33342 for 20 min. After another wash, cells were imaged by an INCell Analyzer 2200 imaging system (GE Healthcare).

Flow cytometry analysis {#S8}
-----------------------

The iPSCs were dissociated using TrypLE Express enzyme (ThermoFisher Scientific), fixed with 4% paraformaldehyde for 10 mins at room temperature and then rinsed with DPBS. Before analysis, cells were permeabilized with 0.2% Tween-20 in DPBS for 10 min at room temperature and stained with fluorophore conjugated antibodies for 1 h at 4 °C on a shaker. Cells were then analyzed on a BD Accuri C6 Flow Cytometry system (BD Biosciences). Antibodies used are listed in [Table 2](#T2){ref-type="table"}.

G-banded karyotyping {#S9}
--------------------

iPSCs were sent to WiCell Research Institute (Madison, WI) for G-banded karyotyping analysis. Experiments followed the standard cytogenetic protocol; results were concluded from 20 metaphase cells.

Short tandem repeat (STR) analysis {#S10}
----------------------------------

STR profiling was conducted at WiCell Research Institute (Madison, WI) using PowerPlex 16 Kit (Promega).

Mycoplasma test {#S11}
---------------

Mycoplasma detection was performed using the MycoAlert mycoplasma detection kit (Lonza). Ratio B/A \> 1.2 indicates mycoplasma positive. Ratio between 0.9-1.2 indicates ambiguous results. Ratio B/A \< 0.9 indicates mycoplasma negative.

Testing for Sendai reprogramming vector clearance {#S12}
-------------------------------------------------

Total RNA was isolated by RNeasy Plus Mini Kit (Qiagen) and cDNA was synthesized from 1 μg of total RNA and random hexamers using Superscript™ III First-Strand Synthesis SuperMix (Thermo Fisher Scientific). PCRs were performed with Platinum II Hot-Start PCR Master Mix (Thermo Fisher Scientific) on Mastercycler pro S (Eppendorf) following a universal amplification setting: 94 °C for 2 min; 30 cycles of (94 °C for 15 s, 60 °C for 15 s) and 68 °C for 15 s. The primers are listed in [Table 2](#T2){ref-type="table"}. The positive control was derived from human fibroblasts (GM05659, Coriell Institute) infected with Sendai virus for four days.

Teratoma formation assay {#S13}
------------------------

Teratoma was generated by a subcutaneous injection procedure. Approximately 1 × 10^7^ hiPSCs were constituted in 400 μL of 25mM HEPES (pH 7.4) solution. Prior to injection, cells were mixed with 200 μL of cold Matrigel (Corning, 354277). The mixture was injected subcutaneously into NSG mice (JAX No. 005557) at two sites (150 μL per injection site). After 6--8 weeks, visible tumors were removed and fixed in 10% Buffer Balanced Formalin. The fixed tumors were embedded in paraffin and stained with hematoxylin and eosin.

Supplementary Material {#SM1}
======================
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![Characterization of TRNDi007-B iPSC line.\
**A)** Left: Phase contrast imaging of TRNDi007-B colonies. Right: Representative immunofluorescent images of iPSCs showing expression of stem cell markers: SOX2, OCT4, SSEA-4, and NANOG. Nucleus is stained with Hoechst dye (in blue). **B)** Flow cytometry analysis of pluripotency protein markers: TRA-1-60, NANOG and SSEA-4. **C)** Cytogenetic analysis showing a normal karyotype (46, XY). **D)** Detection of homozygous mutation of c.2560 C \> T in exon 18 of the *GAA* gene. **E)** RT-PCR verification of the clearance of Sendai virus from the reprogrammed cells. Sendai virus vector transduced fibroblasts was used as positive control. **F)** Histological analysis of teratomas produced by TRNDi007-B iPSCs. Representative images showing the presence of ectodermal, endodermal and mesodermal derivatives.](nihms-1530904-f0001){#F1}

###### 

Characterization and validation.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification                        Test                                   Result                                                                                                                        Data
  ------------------------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Morphology                            Photography                            Normal                                                                                                                        [Fig. 1](#F1){ref-type="fig"} Panel A

  Phenotype                             Immunocytochemistry                    SOX2, OCT4, NANOG, SSEA-4                                                                                                     [Fig. 1](#F1){ref-type="fig"} Panel A

                                        Flow cytometry                         TRA-1-60 (97.1%); NANOG (87.4%); SSEA-4 (99.9%)                                                                               [Fig. 1](#F1){ref-type="fig"} Panel B

  Genotype                              Karyotype (G-banding) and resolution   46XY\                                                                                                                         [Fig. 1](#F1){ref-type="fig"} Panel C
                                                                               Resolution: 350--400                                                                                                          

  Identity                              Microsatellite PCR (mPCR) OR           Not performed                                                                                                                 N/A

                                        STR analysis                           16 sites tested, all sites matched                                                                                            Available with the authors

  Mutation analysis (IF APPLICABLE)     Sequencing                             Homozygous mutation of *GAA* C.2560C \> T in exon 18                                                                          [Fig. 1](#F1){ref-type="fig"} Panel D

  Southern Blot OR WGS                  N/A                                    N/A                                                                                                                           

  Microbiology and virology             Mycoplasma                             Mycoplasma testing by luminescence. Negative                                                                                  [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}

  Differentiation potential             Teratoma formation                     Teratoma with three germlayers formation. Ectoderm (pigment epithelium); Mesoderm (cartilage); Endoderm (gut-like endoderm)   [Fig. 1](#F1){ref-type="fig"} Panel F

  Donor screening (OPTIONAL)            HIV 1+2 Hepatitis B, Hepatitis C       N/A                                                                                                                           N/A

  Genotype additional info (OPTIONAL)   Blood group genotyping                 N/A                                                                                                                           N/A

  HLA tissue typing                     N/A                                    N/A                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Reagents details.

  Antibodies used for immunocytochemistry/flow-citometry                                                      
  -------------------------------------------------------- ----------------------------------------- -------- --------------------------------------------------------
  Pluripotency Markers                                     Mouse anti-SOX2                           1:50     R&D Systems, Cat\# MAB2018, RRID:AB_358009
  Pluripotency Markers                                     Mouse anti-SSEA-4                         1:1000   Cell Signaling Technology, Cat\# 4755, RRID:AB_1264259
  Pluripotency Markers                                     Rabbit anti-NANOG                         1:400    Cell Signaling Technology Cat\# 4903, RRID:AB_10559205
  Pluripotency Markers                                     Rabbit anti-OCT4A                         1:400    Thermo Fisher Cat\# A13998, RRID:AB_2534182
  Secondary antibodies                                     Donkey anti-Mouse IgG (Alexa Fluor 488)   1:400    Thermo Fisher, Cat\# A21202, RRID: AB_141607
  Secondary antibodies                                     Donkey anti-Rabbit IgG                    1:400    Thermo Fisher, Cat\# A21207, RRID: AB_141637
  Flow cytometry antibodies                                Anti-Tra-1-60-DyLight 488                 1:50     Thermo Fischer, Cat\# MA1--023-D488X, RRID: AB_2536700
  Flow cytometry antibodies                                Anti-Nanog-Alexa Fluor 488                1:50     Millipore, Cat\# FCABS352A4, RRID: AB_10807973
  Flow cytometry antibodies                                Anti-SSEA-4-Alexa Fluor 488               1:50     Thermo Fischer, Cat\# 53--8843-41, RRID: AB_10597752
  Flow cytometry antibodies                                Mouse-IgM-DyLight 488                     1:50     Thermo Fischer, Cat\# MA1--194-D488, RRID: AB_2536969
  Flow cytometry antibodies                                Rabbit IgG-Alexa Fluor 488                1:50     Cell Signaling, Cat\# 4340S, RRID: AB_10694568
  Flow cytometry antibodies                                Mouse IgG3-FITC                           1:50     Thermo Fischer, Cat\# 11--4742-42, RRID: AB_2043894

###### 

Resource table.

  --------------------------------------- --------------------------------------------------------------------------------------
  Unique stem cell line identifier        TRNDi007-B

  Alternative name(s) of stem cell line   HT521B

  Institution                             National Institutes of Health\
                                          National Center for Advancing Translational Sciences Bethesda, Maryland, USA

  Contact information of distributor      Dr. Wei Zheng\
                                          <Wei.Zheng@nih.gov>

  Type of cell line                       iPSC

  Origin                                  Human

  Additional origin info                  Age: five-month\
                                          Sex: Male\
                                          Ethnicity: African American

  Cell source                             Skin fibroblasts

  Clonality                               Clonal

  Method of reprogramming                 Integration-free Sendai viral vectors

  Genetic modification                    NO

  Type of modification                    N/A

  Associated disease                      Pompe disease

  Gene/locus                              GAA, chromosomal location:17q25.2-q25.3, genotype: exon 18, C.2560C \> T (p.R854X)

  Method of modification                  N/A

  Name of transgene or resistance         N/A

  Inducible/constitutive system           N/A

  Date archived/stock date                2017

  Cell line repository/bank               N/A

  Ethical approval                        NIGMS Informed Consent Form was obtained from patient at time of sample submission.\
                                          Confidentiality Certificate: CC-GM-15-004
  --------------------------------------- --------------------------------------------------------------------------------------
